<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583453</url>
  </required_header>
  <id_info>
    <org_study_id>200703765</org_study_id>
    <nct_id>NCT00583453</nct_id>
  </id_info>
  <brief_title>Celecoxib as a Post-tonsillectomy Pain Medication</brief_title>
  <official_title>Perioperative Use of Celecoxib to Improve Pain Control in Patients Undergoing Tonsillectomy: a Randomized, Double Blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that celecoxib effectively reduces pain after a tonsillectomy and reduces
      post-operative narcotic use.

      To test this hypothesis, the study is placebo controlled (sugar pill). Half of the
      participants will receive a sugar pill, half will not.

      All participants will receive the standard post-operative pain medications.

      We ask participants to log the amount of medications they use daily, and the amount of pain
      they have each day. It is hoped that celecoxib will reduce the amount of post-operative pain
      medication needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-tonsillectomy pain is typically controlled through narcotic medications, such as Lortab
      elixir. Despite its standard use, this pain control is typically not as effective as a
      non-steroidal anti-inflammatory medication (NSAID). The problem with using NSAIDs for
      post-tonsillectomy operative pain is the significant increased risk of rebleeding.

      Celecoxib is an NSAID that is a COX-2 inhibitor; the drug is designed to act as an NSAID
      without the increased risk of rebleeding or hemorrhage.

      This study is a double blind, randomized study; neither the study participant or the study
      investigator knows if the participant is receiving celecoxib or a placebo (sugar pill). The
      blinded list is maintained by the research pharmacists and can be unblinded when needed (such
      as in an emergency).

      Participants begin taking the study medication the night before surgery and continue through
      10 days post-operative. Participants are asked to complete a journal that catalogs the amount
      of standard post-operative medications taken, the amount of pain experienced, and any other
      comments.

      Participants are contacted by phone at 5 and 10 days post-op.

      Study participation ends at the standard 3-week post-operative check-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported Pain Score</measure>
    <time_frame>day of procedure through post-operative day 10</time_frame>
    <description>Pain score as reported by participant, measured on a 10 point scale, where 0 = none and 10 = unbearable, collected once daily.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported Activity Level</measure>
    <time_frame>From operative day through 10 days post-operative</time_frame>
    <description>Activity level, reported by participant utilizing a 10-point ordinal scale (0 = no activity, 10 = return to normal activities). Activity level was measured was collected once daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen Equivalent Use</measure>
    <time_frame>From operative day through 10 days post-operative</time_frame>
    <description>Participant reported acetaminophen use and its equivalent. Medication use was collected from reported participant journals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Post-operative Hemorrhage</measure>
    <time_frame>From operative day through 10 days post-operative</time_frame>
    <description>The incidence of post-operative hemorrhage, defined as post-operative bleeding requiring medical intervention or hospitalization during the 10 day post-operative follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Morphine Equivalent</measure>
    <time_frame>From operative day through 10 days post-operative</time_frame>
    <description>Participant reported mophine equivalent use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Tonsillitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with same dosing schedule as the active comparator arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years

          -  Indication for tonsillectomy (patients undergoing a tonsillectomy as a portion of
             additional surgical procedures will not be included)

          -  Have the ability to understand and the willingness to sign a written informed consent
             document

        Exclusion Criteria:

          -  History of bleeding disorders

          -  History of liver or kidney dysfunction

          -  History of allergy to sulfa containing medications

          -  History of lactose intolerance

          -  History of asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs

          -  Women who are currently pregnant, nursing, or trying to conceive

          -  History of allergy or intolerance to acetaminophen or hydrocodone

          -  History of allergy to any COX-2 inhibitor, including celecoxib or rofecoxib.

          -  PT, PTT, hemoglobin, or hematocrit values that are outside of institutional limits.

          -  History of cardiovascular disease

          -  Patients currently taking celecoxib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas VanDaele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otolaryngologyâ€”Head &amp; Neck Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Van Daele DJ, Bodeker KL, Trask DK. Celecoxib Versus Placebo in Tonsillectomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial. Ann Otol Rhinol Laryngol. 2016 Oct;125(10):785-800. doi: 10.1177/0003489416654707. Epub 2016 Jun 29.</citation>
    <PMID>27357971</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <results_first_submitted>February 12, 2017</results_first_submitted>
  <results_first_submitted_qc>February 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>February 12, 2017</last_update_submitted>
  <last_update_submitted_qc>February 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Douglas J Van Daele</investigator_full_name>
    <investigator_title>Associate Professor of Otolaryngologyâ€”Head &amp; Neck Surgery</investigator_title>
  </responsible_party>
  <keyword>Tonsillectomy</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Pain measurement</keyword>
  <keyword>Celecoxib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be uploaded through clinicaltrials.gov data tables</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Celecoxib as Experimerimental Intervention</title>
          <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
        </group>
        <group group_id="P2">
          <title>Placebo Control, Active Comparator</title>
          <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>discontinued intervention</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib 200 mg Tablets</title>
          <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
        </group>
        <group group_id="B2">
          <title>Placebo With Same Dosing Schedule as the Active Comparator Arm</title>
          <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="4.1"/>
                    <measurement group_id="B2" value="25.0" spread="3.3"/>
                    <measurement group_id="B3" value="25.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Self-reported Pain Score</title>
        <description>Pain score as reported by participant, measured on a 10 point scale, where 0 = none and 10 = unbearable, collected once daily.</description>
        <time_frame>day of procedure through post-operative day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg Tablets</title>
            <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Same Dosing Schedule as the Active Comparator Arm</title>
            <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Pain Score</title>
          <description>Pain score as reported by participant, measured on a 10 point scale, where 0 = none and 10 = unbearable, collected once daily.</description>
          <units>pain score (units on a scale)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum pain, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.6"/>
                    <measurement group_id="O2" value="6.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maximum pain, averaged across days 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.6"/>
                    <measurement group_id="O2" value="6.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maximum pain, averaged across days 5 to 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.6"/>
                    <measurement group_id="O2" value="5.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maximum pain, averaged across days 8 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.6"/>
                    <measurement group_id="O2" value="4.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average pain, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="1.0"/>
                    <measurement group_id="O2" value="7.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average pain, averaged across days 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.9"/>
                    <measurement group_id="O2" value="7.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average pain, averaged across days 5 to 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="0.9"/>
                    <measurement group_id="O2" value="7.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average pain, averaged across days 8 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.9"/>
                    <measurement group_id="O2" value="5.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with drinking, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.9"/>
                    <measurement group_id="O2" value="6.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with drinking, averaged across days 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.8"/>
                    <measurement group_id="O2" value="6.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with drinking, averaged across days 5 to 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.8"/>
                    <measurement group_id="O2" value="5.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with drinking, averaged across days 8 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.8"/>
                    <measurement group_id="O2" value="4.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.9"/>
                    <measurement group_id="O2" value="4.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.674</p_value>
            <p_value_desc>Treatment x day interaction</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-reported Activity Level</title>
        <description>Activity level, reported by participant utilizing a 10-point ordinal scale (0 = no activity, 10 = return to normal activities). Activity level was measured was collected once daily.</description>
        <time_frame>From operative day through 10 days post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib as Experimerimental Intervention</title>
            <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control, Active Comparator</title>
            <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Activity Level</title>
          <description>Activity level, reported by participant utilizing a 10-point ordinal scale (0 = no activity, 10 = return to normal activities). Activity level was measured was collected once daily.</description>
          <units>Activity score (units on a scale)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.9"/>
                    <measurement group_id="O2" value="4.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.7"/>
                    <measurement group_id="O2" value="4.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 5 to 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.7"/>
                    <measurement group_id="O2" value="3.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 8 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="0.7"/>
                    <measurement group_id="O2" value="5.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Treatment x day interaction reported as 0.018.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acetaminophen Equivalent Use</title>
        <description>Participant reported acetaminophen use and its equivalent. Medication use was collected from reported participant journals.</description>
        <time_frame>From operative day through 10 days post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib as Experimerimental Intervention</title>
            <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control, Active Comparator</title>
            <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Equivalent Use</title>
          <description>Participant reported acetaminophen use and its equivalent. Medication use was collected from reported participant journals.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2074" spread="407"/>
                    <measurement group_id="O2" value="3006" spread="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2245" spread="356"/>
                    <measurement group_id="O2" value="2934" spread="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 5 to 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2028" spread="356"/>
                    <measurement group_id="O2" value="3610" spread="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 8 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1418" spread="356"/>
                    <measurement group_id="O2" value="2483" spread="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.214</p_value>
            <p_value_desc>Treatment x day interaction = 0.214</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Post-operative Hemorrhage</title>
        <description>The incidence of post-operative hemorrhage, defined as post-operative bleeding requiring medical intervention or hospitalization during the 10 day post-operative follow-up period.</description>
        <time_frame>From operative day through 10 days post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg Tablets</title>
            <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Same Dosing Schedule as the Active Comparator Arm</title>
            <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Post-operative Hemorrhage</title>
          <description>The incidence of post-operative hemorrhage, defined as post-operative bleeding requiring medical intervention or hospitalization during the 10 day post-operative follow-up period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Morphine Equivalent</title>
        <description>Participant reported mophine equivalent use</description>
        <time_frame>From operative day through 10 days post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib as Experimerimental Intervention</title>
            <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control, Active Comparator</title>
            <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Total Morphine Equivalent</title>
          <description>Participant reported mophine equivalent use</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="11.6"/>
                    <measurement group_id="O2" value="55.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="9.6"/>
                    <measurement group_id="O2" value="72.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 5 to 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="9.6"/>
                    <measurement group_id="O2" value="69.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average, days 8 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="9.6"/>
                    <measurement group_id="O2" value="38.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>treatment x day interaction P = 0.036 Treatment main effect (average day 1 to 10) P = 0.003</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks postoperatively</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib as Experimerimental Intervention</title>
          <description>Celecoxib 200 mg tablets
Celecoxib: Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control, Active Comparator</title>
          <description>Placebo with same dosing schedule as the active comparator arm
Placebo: Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting, grade 1</sub_title>
                <description>A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.</description>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysphagia, grade 2</sub_title>
                <description>A disorder characterized by difficulty in swallowing. Grade 2 = symptomatic and altered eating / swallowing</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration, grade 2</sub_title>
                <description>A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or lack of adequate fluid intake.
Grade 2: I.V. fluids indicated for less than 24 hours</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size Disproportionately female population</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Douglas Van Daele</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-353-8162</phone>
      <email>douglas-van-daele@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

